# Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine

> **NCT00482027** · PHASE1 · COMPLETED · sponsor: **International AIDS Vaccine Initiative** · enrollment: 80 (actual)

## Conditions studied

- HIV Infection

## Interventions

- **BIOLOGICAL:** tgAAC09

## Key facts

- **NCT ID:** NCT00482027
- **Lead sponsor:** International AIDS Vaccine Initiative
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2006-12
- **Final completion:** 2007-01
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2013-01-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00482027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00482027, "Safety and Immunogenicity Study of tgAAC09, a Gag-PR-RT AAV HIV Vaccine". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00482027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*